Cagrilintide

Long-acting amylin analogue · sold as “Amylix”

Investigational long-acting amylin analogue studied alone and combined with semaglutide (CagriSema).

InvestigationalWeight & Metabolism

Not FDA-approved. Investigational (Novo Nordisk). CagriSema regulatory submission reported; not approved at last review. This page describes research and public discussion; it is not a recommendation to use.

Overview

Cagrilintide mimics amylin, a hormone co-released with insulin that promotes fullness. Brochure product “Amylix” is described as amylin-based; we profile cagrilintide as the leading clinical amylin analogue. Confirm the actual molecule with any supplier.

Mechanism of action

Agonist at amylin and calcitonin receptors in the brainstem and hypothalamus, increasing satiety and slowing gastric emptying.

Benefits & evidence ratings

~10.8% weight loss at 2.4 mg monotherapy over 26 weeks (phase 2)B Human clinical data

~20% weight loss combined with semaglutide (REDEFINE 1, CagriSema)B Human clinical data

Dosing

Doses show what has been studied or discussed — not guidance. Always follow your prescriber.

Source	Dose	Frequency	Duration	Route
Phase 2 dose-finding (Lancet 2021) B Human clinical data	0.3–4.5 mg	Once weekly	26 weeks	Subcutaneous
REDEFINE 1 (with semaglutide 2.4 mg) B Human clinical data	2.4 mg	Once weekly	68 weeks	Subcutaneous

Clinical trials & studies

Phase 22021
Once-weekly cagrilintide for weight management (Lancet)
Phase 2; dose-dependent weight loss up to 10.8%.
Phase 32025
Cagrilintide–Semaglutide in Adults with Overweight or Obesity (REDEFINE 1, NEJM)
Mean −20.4% vs −3.0% placebo.

Safety

Side effects

Nausea, constipation, diarrhea
Fatigue
Injection-site reactions

Contraindications

Pregnancy
Gastroparesis (theoretical, slows emptying)

Interactions

Insulin — hypoglycemia risk (pramlintide class warning)
Additive GI effects with GLP-1 agonists

Long-term safety

Limited to trial durations (~68 weeks).

Regulatory status

Investigational

Investigational (Novo Nordisk). CagriSema regulatory submission reported; not approved at last review.

FAQ

Commonly discussed alongside

Semaglutide

Listing a combination does not mean it has been studied or is safe.

Considering a GLP-1 for weight loss?

Compare licensed telehealth providers by true monthly cost and care quality.

See your top 3 matches